Bank of New York Mellon Corp increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 333,942 shares of the biopharmaceutical company’s stock after acquiring an additional 28,260 shares during the period. Bank of New York Mellon Corp owned about 0.39% of Alnylam Pharmaceuticals worth $26,634,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. CIBC Asset Management Inc acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $221,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $148,000. Capstone Asset Management Co. bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $232,000. Hemenway Trust Co LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $235,000. Finally, Westpac Banking Corp bought a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $202,000. Institutional investors and hedge funds own 94.27% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 79.49 on Wednesday. The company has a 50-day moving average price of $81.88 and a 200-day moving average price of $67.94. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $89.45. The company’s market capitalization is $7.29 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same period in the previous year, the business posted ($1.05) earnings per share. The company’s revenue for the quarter was up 82.9% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.18) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.themarketsdaily.com/2017/09/13/bank-of-new-york-mellon-corp-acquires-28260-shares-of-alnylam-pharmaceuticals-inc-alny.html.
A number of equities analysts have weighed in on the stock. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday. Stifel Nicolaus reissued a “buy” rating and set a $56.00 price target (up from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Leerink Swann restated a “market perform” rating and set a $72.00 price objective (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 8th. They noted that the move was a valuation call. BMO Capital Markets restated an “outperform” rating and set a $99.00 price objective (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Finally, Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an “equal weight” rating in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $83.50.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.